JTT 608

Known as: JTT-608 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2005
0119982005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
AIM Chronic glycaemic control, in particular, the control of postprandial hyperglycaemia, is essential for preventing the… (More)
Is this relevant?
2003
2003
We investigated the chronic effect of a new antidiabetic agent, trans-4-(methylcyclohexyl)-4-oxobutyric acid (JTT-608), in Goto… (More)
Is this relevant?
2001
2001
Insulin secretion from MIN6 cells (a pancreatic beta-cell line) induced by high glucose (greater than 16.8 mM) was potentiated by… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2001
2001
A new nonsulfonylurea oral hypoglycemic agent, JTT-608, has been reported to stimulate insulin release at elevated, but not low… (More)
Is this relevant?
2000
2000
We examined the effects of the novel hypoglycaemic agent JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid] on insulin… (More)
Is this relevant?
1999
1999
1. We investigated the pharmacological effects of a new antidiabetic agent, JTT-608, in comparison with the sulphonylurea… (More)
Is this relevant?
1999
1999
We investigated the pharmacological effects of a new anti-hyperglycemic agent, JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric… (More)
Is this relevant?
1999
1999
The effects of JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid], a novel antidiabetic compound, on insulin secretion were… (More)
Is this relevant?
1998
1998
During an investigation of drugs for improving the beta-cell response to glucose, we found that 4-cyclohexyl-4-oxobutyric acid… (More)
Is this relevant?